🏢 公司Newsroom01099 国药控股Codex · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 17:24:01·⟳ 抓取 17:24:05 +4s·⚡ 决策 08-31 21:33:35 +4h09m·57.3 天前
国药控股发布临时股东大会通知，议案为董事会成员重选
公告内容属于例行治理程序和董事重选安排，没有新增业绩、订单、资本配置或监管事实，无法形成方向性交易边际。
📄 原文01099 国药控股↗ 原文
Announcements and Notices - NOTICE OF EXTRAORDINARY GENERAL MEETING pdf
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the con…
不做 国药控股（01099.HK）
例行EGM与董事重选通知，无经营、财务、资本结构或监管增量，缺乏方向性edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
国药控股本次一手公告只是通知临时股东大会并列明董事重选议案，未显示管理层控制权变化、薪酬异常、资产交易、业务合作或财务增量；即使补充行情或外部搜索，也不会改变该事件本身缺乏交易催化的结论。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
主要风险
- 本事件不构成公司级新增净利空或净利好，不能据此建立方向性仓位。
先例如何影响了这次决策
对本次决策的影响:先例不足不影响结论，因公告文本已足以判断缺乏可交易增量。
方向:例行股东大会通知和董事重选公告通常不提供独立方向性交易信号。
涨幅量级:无可用于校准涨跌幅的有效同类催化，因为本事件没有经营或资本市场增量。
形态:不适用；事件本身不是价格重估型催化。
原文全文
展开原文 · 12,044 字
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no
responsibility for the contents of this notice, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or
in reliance upon the whole or any part of the contents of this notice.
SINOPHARM GROUP CO. LTD.*
(A joint stock limited company incorporated in the People’s Republic of China with limited
liability and carrying on business in Hong Kong as )
(Stock Code: 01099)
NOTICE OF EXTRAORDINARY GENERAL MEETING
NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “EGM”) of Sinopharm
Group Co. Ltd. (the “Company”) will be held at 9:00 a.m. on Tuesday, 15 September 2026 at
Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District,
Shanghai, the People’s Republic of China (the “PRC”), for the purpose of considering, and if thought
fit, passing the following resolutions:
Ordinary Resolutions
1. To consider and approve (if thought fit) the re-election of Mr. Lian Wanyong as an executive
Director of the seventh session of the board of the Company (the “Board”), and to authorize the
Board to determine his remuneration and to authorize the chairman of the Board (the
“Chairman”) or any executive Director of the Company to enter into the service contract or
such other documents or supplemental agreements or deeds with him.
2. To consider and approve (if thought fit) the re-election of Mr. Yang Binghua as an executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
3. To consider and approve (if thought fit) the re-election of Mr. Jin Bin as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance
under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
- 1 -
4. To consider and approve (if thought fit) the re-election of Mr. Chen Qiyu as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
5. To consider and approve (if thought fit) the re-election of Mr. Zu Jing as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
6. To consider and approve (if thought fit) the re-election of Mr. Xing Yonggang as a non-
executive Director of the seventh session of the Board, and to authorize the Board to determine
his remuneration and to authorize the Chairman or any executive Director of the Company to
enter into the service contract or such other documents or supplemental agreements or deeds
with him.
7. To consider and approve (if thought fit) the re-election of Mr. Ma Yue as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
8. To consider and approve (if thought fit) the re-election of Mr. Chen Yuqing as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
9. To consider and approve (if thought fit) the re-election of Mr. Wen Deyong as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
10. To consider and approve (if thought fit) the re-election of Ms. Li Ying as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine her
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with her.
- 2 -
11. To consider and approve (if thought fit) the re-election of Mr. Li Peiyu as an independent non-
executive Director of the seventh session of the Board, and to authorize the Board to determine
his remuneration and to authorize the Chairman or any executive Director of the Company to
enter into the service contract or such other documents or supplemental agreements or deeds
with him.
12. To consider and approve (if thought fit) the re-election of Mr. Wu Tak Lung as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
13. To consider and approve (if thought fit) the re-election of Mr. Yu Weifeng as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
14. To consider and approve (if thought fit) the re-election of Mr. Shi Shenghao as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
15. To consider and approve (if thought fit) the re-election of Mr. Chen Weiru as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
By Order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
31 August 2026
As at the date of this notice, the executive Directors of the Company are Mr. Lian Wanyong and Mr.
Yang Binghua; the non-executive Directors of the Company are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu
Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the
independent non-executive Directors of the Company are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu
Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
- 3 -
Notes:
1. In accordance with the Articles of Association, for the purpose of holding the EGM, the register of
members of the Company will be closed from Thursday, 10 September 2026 to Tuesday, 15 September
2026 (both days inclusive), during which no transfer of Shares of the Company can be registered.
In order to be qualified to attend and vote at the EGM, for holders of H Shares, all transfer documents
accompanied by the relevant share certificates must be lodged with the H Shares registrar of the
Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor,
Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong as soon as practicable, and in any event
no later than 4:30 p.m. on Wednesday, 9 September 2026.
Shareholders whose names appear on the register of members on Thursday, 10 September 2026 are
entitled to attend and vote at the EGM.
2. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend
and vote on their behalves. A proxy need not be a Shareholder of the Company.
3. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his attorney
duly authorised in writing. If the Shareholder is a legal person, that instrument must be executed either
under its seal or under the hand of its director or other attorney duly authorised to sign the same.
4. In order to be valid, the proxy form must be deposited, for the holders of H Shares, to the H Shares
registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell
Centre, 183 Queen’s Road East, Wanchai, Hong Kong, or for the holders of Domestic Shares, to the
office of the Company in the PRC not less than 24 hours before the time appointed for holding the EGM
or any adjourned thereof. If the proxy form is signed by a person under a power of attorney or other
authority, a notarially certified copy of that power of attorney or other authority shall be deposited at the
same place as mentioned in the proxy form. Completion and return of the proxy form will not preclude
Shareholders from attending and voting in person at the EGM or any adjourned meetings should you so
wish.
5. Individual Shareholders shall produce their identity documents and supporting documents in respect of
the shares of the Company held when attending the EGM. If corporate Shareholders appoint authorised
representative to attend the EGM, the authorised representative shall produce his/her identity documents
and a notarially certified copy of the relevant authorisation instrument signed by the board of directors or
other authorised parties of the corporate Shareholders or other notarially certified documents allowed by
the Company. Proxies shall produce their identity documents and the proxy form signed by the
Shareholders or their attorney when attending the EGM.
6. The EGM is expected to take less than half a day. Shareholders attending the EGM shall be responsible
for their own travel and accommodation expenses.
7. Contact details of the office of the Company in the PRC are as follows:
Address: Room 1413, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District,
Shanghai, 200023, the PRC
Telephone No.: (86 21) 2305 2147
Fax No.: (86 21) 2305 2146
- 4 -
responsibility for the contents of this notice, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or
in reliance upon the whole or any part of the contents of this notice.
SINOPHARM GROUP CO. LTD.*
(A joint stock limited company incorporated in the People’s Republic of China with limited
liability and carrying on business in Hong Kong as )
(Stock Code: 01099)
NOTICE OF EXTRAORDINARY GENERAL MEETING
NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “EGM”) of Sinopharm
Group Co. Ltd. (the “Company”) will be held at 9:00 a.m. on Tuesday, 15 September 2026 at
Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District,
Shanghai, the People’s Republic of China (the “PRC”), for the purpose of considering, and if thought
fit, passing the following resolutions:
Ordinary Resolutions
1. To consider and approve (if thought fit) the re-election of Mr. Lian Wanyong as an executive
Director of the seventh session of the board of the Company (the “Board”), and to authorize the
Board to determine his remuneration and to authorize the chairman of the Board (the
“Chairman”) or any executive Director of the Company to enter into the service contract or
such other documents or supplemental agreements or deeds with him.
2. To consider and approve (if thought fit) the re-election of Mr. Yang Binghua as an executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
3. To consider and approve (if thought fit) the re-election of Mr. Jin Bin as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance
under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
- 1 -
4. To consider and approve (if thought fit) the re-election of Mr. Chen Qiyu as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
5. To consider and approve (if thought fit) the re-election of Mr. Zu Jing as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
6. To consider and approve (if thought fit) the re-election of Mr. Xing Yonggang as a non-
executive Director of the seventh session of the Board, and to authorize the Board to determine
his remuneration and to authorize the Chairman or any executive Director of the Company to
enter into the service contract or such other documents or supplemental agreements or deeds
with him.
7. To consider and approve (if thought fit) the re-election of Mr. Ma Yue as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
8. To consider and approve (if thought fit) the re-election of Mr. Chen Yuqing as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
9. To consider and approve (if thought fit) the re-election of Mr. Wen Deyong as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine his
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with
him.
10. To consider and approve (if thought fit) the re-election of Ms. Li Ying as a non-executive
Director of the seventh session of the Board, and to authorize the Board to determine her
remuneration and to authorize the Chairman or any executive Director of the Company to enter
into the service contract or such other documents or supplemental agreements or deeds with her.
- 2 -
11. To consider and approve (if thought fit) the re-election of Mr. Li Peiyu as an independent non-
executive Director of the seventh session of the Board, and to authorize the Board to determine
his remuneration and to authorize the Chairman or any executive Director of the Company to
enter into the service contract or such other documents or supplemental agreements or deeds
with him.
12. To consider and approve (if thought fit) the re-election of Mr. Wu Tak Lung as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
13. To consider and approve (if thought fit) the re-election of Mr. Yu Weifeng as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
14. To consider and approve (if thought fit) the re-election of Mr. Shi Shenghao as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
15. To consider and approve (if thought fit) the re-election of Mr. Chen Weiru as an independent
non-executive Director of the seventh session of the Board, and to authorize the Board to
determine his remuneration and to authorize the Chairman or any executive Director of the
Company to enter into the service contract or such other documents or supplemental agreements
or deeds with him.
By Order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
31 August 2026
As at the date of this notice, the executive Directors of the Company are Mr. Lian Wanyong and Mr.
Yang Binghua; the non-executive Directors of the Company are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu
Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the
independent non-executive Directors of the Company are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu
Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
- 3 -
Notes:
1. In accordance with the Articles of Association, for the purpose of holding the EGM, the register of
members of the Company will be closed from Thursday, 10 September 2026 to Tuesday, 15 September
2026 (both days inclusive), during which no transfer of Shares of the Company can be registered.
In order to be qualified to attend and vote at the EGM, for holders of H Shares, all transfer documents
accompanied by the relevant share certificates must be lodged with the H Shares registrar of the
Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor,
Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong as soon as practicable, and in any event
no later than 4:30 p.m. on Wednesday, 9 September 2026.
Shareholders whose names appear on the register of members on Thursday, 10 September 2026 are
entitled to attend and vote at the EGM.
2. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend
and vote on their behalves. A proxy need not be a Shareholder of the Company.
3. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his attorney
duly authorised in writing. If the Shareholder is a legal person, that instrument must be executed either
under its seal or under the hand of its director or other attorney duly authorised to sign the same.
4. In order to be valid, the proxy form must be deposited, for the holders of H Shares, to the H Shares
registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell
Centre, 183 Queen’s Road East, Wanchai, Hong Kong, or for the holders of Domestic Shares, to the
office of the Company in the PRC not less than 24 hours before the time appointed for holding the EGM
or any adjourned thereof. If the proxy form is signed by a person under a power of attorney or other
authority, a notarially certified copy of that power of attorney or other authority shall be deposited at the
same place as mentioned in the proxy form. Completion and return of the proxy form will not preclude
Shareholders from attending and voting in person at the EGM or any adjourned meetings should you so
wish.
5. Individual Shareholders shall produce their identity documents and supporting documents in respect of
the shares of the Company held when attending the EGM. If corporate Shareholders appoint authorised
representative to attend the EGM, the authorised representative shall produce his/her identity documents
and a notarially certified copy of the relevant authorisation instrument signed by the board of directors or
other authorised parties of the corporate Shareholders or other notarially certified documents allowed by
the Company. Proxies shall produce their identity documents and the proxy form signed by the
Shareholders or their attorney when attending the EGM.
6. The EGM is expected to take less than half a day. Shareholders attending the EGM shall be responsible
for their own travel and accommodation expenses.
7. Contact details of the office of the Company in the PRC are as follows:
Address: Room 1413, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District,
Shanghai, 200023, the PRC
Telephone No.: (86 21) 2305 2147
Fax No.: (86 21) 2305 2146
- 4 -
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。